Table 1 Baseline demographics, clinical characteristics, and patient treatments at the end of follow-up (24 months)
Characteristics | RA and UA patients (n = 118) |
|---|---|
Age (mean ± SD) | 53 ± 15.66 |
Gender (% females) | 80.5 |
Symptoms duration (weeks mean ± SEM) | 53.79±8.72 |
RF positive (%), mean (SD) | 8.4, [35.6 (167.9)] |
ACPA positive (%), mean (SD) | 16, [21.9 (50.8)] |
ESR (mean ± SEM, mm/h) | 30.46 ± 2.36 |
CRP (mean ± SEM, mg/dL) | 1.96 ± 0.35 |
Disease activity score 28 joints (DAS28) (mean ± SEM) | 4.85 ± 0.14 |
Treatments during 24 months of follow-up,N(% of all patients) | |
Biologic DMARD +/− csDMARDs | 16 (13.6) |
Methotrexate | 45 (38.1) |
Leflunomide | 26 (22) |
HCQ | 31 (26.3) |
Corticosteroids per os | 11 (9.3) |